Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Colorectal Cancer Health Center

Font Size

FDA Approves New Colon Cancer Drug

Vectibix Follows Chemotherapy for Colorectal Cancer That Has Spread

Drug's Trials continued...

Overall survival was similar for both groups during the 48-week study.

"Almost everyone had progressed by 48 weeks," J. Randolph Hecht, MD, tells WebMD. By "progressed," he means their tumors had worsened.

"But at eight weeks, the first look, 70% of the people had progressed on best supportive care, while only 51% had progressed [with] Vectibix," Hecht says. "That 20% or so difference persisted for awhile. By the time you get to 32 weeks it was not a big difference."

Hecht has conducted U.S. studies of Vectibix, but he wasn't involved in the European trial. He directs the gastrointestinal oncology program at the University of California, Los Angeles.

In addition, tumors shrank in 8% of the patients taking Vectibix. In some cases, those tumors shrank to less than half of their pretreatment size.

"At every time point that you looked at, if you were in the Vectibix arm you were much less likely to have your tumor progress than if you were on the best supportive care arm," Hecht says.

"That's another way of looking at that," says Hecht.

Side Effects

The most serious adverse events in the Vectibix studies included pulmonary fibrosis (the formation of fibrous tissue in the lungs), severe skin rashcomplicated by infections, infusion reactions, abdominal pain, nausea, vomiting, and constipation.

The most common adverse events associated with the drug included skin rash, fatigue, abdominal pain, nausea, and diarrhea.

Vectibix is made by Amgen, Inc. The drug company has committed to conduct a postmarketing trial to show whether Vectibix improves patients' survival in patients with fewer prior chemotherapies.

1 | 2

Today on WebMD

Colorectal cancer cells
The right diagnosis is the most important factor.
man with a doctor
Our health check will steer you in the right direction.
sauteed cherry tomatoes
Fight cancer one plate at a time.
bladder cancer x-ray
Do you know the warning signs?
Colon vs Rectal Cancer
New Colorectal Treatments
can lack of sleep affect your immune system
Cancer Facts Quiz
Virtual Colonoscopy
Picture of the Colon
Vitamin D